# Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder

> **NCT00235508** · PHASE4 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 420 (actual)

## Conditions studied

- Insomnia
- Generalized Anxiety Disorder

## Interventions

- **DRUG:** Eszopiclone (Lunesta)

## Key facts

- **NCT ID:** NCT00235508
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2006-04
- **Final completion:** 2006-04
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2012-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00235508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00235508, "Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00235508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*